Overcoming Barriers in Type 2 Diabetes Management with Individualized Treatment Strategies

San Diego, CA US

Thursday, March 5, 2015 | 6:30 – 9:30 PM PST
Hilton San Diego Bayfront Hotel, Sapphire Ballroom B

This course is a live CME-certified ancillary symposium presented at ENDO 2015, the Endocrine Society's 97th Annual Meeting and Expo, held in San Deigo, California, March 5–8, 2015. ENDO 2015 ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC). There is no cost to attend, and all ENDO 2015 attendees are welcome; however, seating is limited and advance registration is recommended. You must be registered for ENDO 2015 to attend an ENDO 2015 ancillary symposium.

This activity is supported by an educational grant from sanofi-aventis U.S. Inc. 


Welcome and Introduction
Program Director: Mary Ann Banerji, MD – SUNY Downstate

Early Initiation of Insulin Therapy
MaryAnn Banerji, MD – SUNY Downstate

Back to Basals: Optimizing Basal Insulin Therapy
Andrew J. Ahmann, MD – Oregon Health & Science University

Management of the Severely Insulin Resistant Patient
Lisa R. Tannock, MD – University of Kentucky

Meeting Targets with New and Emerging Therapies
Jack L. Leahy, MD – University of Vermont

Roundtable Discussion

Target Audience

This program should be of substantial interest to: endocrinologists and endocrine fellows, primary care and internal medicine physicians, physician’s assistants, nurse practitioners and other healthcare professionals caring for individuals with type 2 diabetes or at risk for developing diabetes.

Learning Objectives

Upon completion of this educational activity, participants will be able to (or better able to):

  • Summarize current clinical findings on the benefits of early insulin initiation on long-term patient outcomes
  • Select the most appropriate basal insulin taking into consideration the various pharmacokinetics of new and emerging formulations
  • Discuss strategies to overcome barriers in initiating insulin and optimizing basal insulin therapy
  • Devise therapeutic strategies for insulin resistant patients taking into consideration new and emerging formulations of concentrated insulins
  • Discuss the benefits and limitations of emerging therapies

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Diabetes and Glucose Metabolism
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 2.50 AMA PRA Category 1 Credits
  • 2.50 CME Certificate of Participation
Course opens: 
Course expires: 
Hilton San Diego Bayfront
1 Park Boulevard
Sapphire Ballroom B
San Diego, CA 92101
United States

MaryAnn Banerji, MD – Program Director
Professor of Medicine
Director, Diabetes Treatment Center
SUNY Downstate Medical Center
Brooklyn, New York

Andrew J. Ahmann, MD
Professor of Medicine
Director, Harold Schnitzer Diabetes Health Center
Oregon Health & Science University
Portland, Oregon

Lisa R. Tannock, MD
Chief, Division of Endocrinology and Molecular Medicine
Associate Chair of Medicine for Administration
University of Kentucky
Lexington, Kentucky

Jack L. Leahy, MD
Professor of Medicine
Chief of Endocrinology, Diabetes and Metabolism
University of Vermont
Colchester, Vermont


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:
Andrew J. Ahmann, MD: Advisory Board Member, AstraZeneca; Planning Group Member, Dexcom; Speaker, Novo Nordisk; Investigator, sanofi
Jack Leahy, MD: Advisory Board Member, Janssesn, Merck, Novo Nordisk, Roche, Sanofi

The following faculty reported no relevant financial relationships:  Lisa Tannock, MD;

The following SPC member who reviewed content for this activity reported relevant financial relationships:
Guillermo E Umpierrez, MD, CDE: Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships: Jeffrey Boord, MD, MPH

The following SPC Committee members reported relevant financial relationships:
Sarah Berga, MD: Advisory Board Member, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.
Paresh Dandona, MD, PhD, FRCP: Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk
Irl B Hirsch, MD: Consultant, Abbott Laboratories, Becton Dickinson, Roche Diagnostics; Grant Support, Halozyme, Sanofi
E. Michael Lewiecki, MD: Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck;
Anton Luger, MD: Advisory Board Member, Investigator and Speaker, Novo Nordisk; Advisory Board Member and Speaker, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Ipsen, Merck, Merck, Sharp & Dome, Novartis, Pfizer, Reckitt Benkiser, Takeda; Investigator, Roche
Lisa Nachtigall, MD: Consultant, Genentech; Consultant and Principal Investigator, Ipsen
Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals
Andrea L Utz, MD, PhD: Investigator, Corcept, Ipsen

The following SPC members reported no relevant financial relationships: Jeffrey Boord, MD, MPH; Larry Fox, MD; Michael S Irwig, MD; Connie B Newman, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.50 AMA PRA Category 1 Credits
  • 2.50 CME Certificate of Participation